Share-based Payment Arrangement, Expense of Y-mAbs Therapeutics, Inc. from 31 Dec 2018 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Y-mAbs Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2018 to 30 Jun 2025.
  • Y-mAbs Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2025 was $2,903,000, a 16% decline year-over-year.
  • Y-mAbs Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2025 was $13,517,000, a 5.5% increase year-over-year.
  • Y-mAbs Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $14,559,000, a 0.73% increase from 2023.
  • Y-mAbs Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $14,453,000.
  • Y-mAbs Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $19,334,000, a 20% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Y-mAbs Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $13,517,000 $2,903,000 -$536,000 -16% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $14,053,000 $3,340,000 -$506,000 -13% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $14,559,000 $3,079,000 -$44,000 -1.4% 01 Oct 2024 31 Dec 2024 10-K 04 Mar 2025 2024 FY
Q3 2024 $14,603,000 $4,195,000 +$1,785,000 +74% 01 Jul 2024 30 Sep 2024 10-Q 08 Nov 2024 2024 Q3
Q2 2024 $12,818,000 $3,439,000 -$177,000 -4.9% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 $12,995,000 $3,846,000 -$1,458,000 -27% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $14,453,000 $3,123,000 01 Oct 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
Q3 2023 $2,410,000 01 Jul 2023 30 Sep 2023 10-Q 08 Nov 2024 2024 Q3
Q2 2023 $3,616,000 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $5,304,000 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1

Y-mAbs Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $14,559,000 +$106,000 +0.73% 01 Jan 2024 31 Dec 2024 10-K 04 Mar 2025 2024 FY
2023 $14,453,000 01 Jan 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
2021 $19,334,000 +$3,199,000 +20% 01 Jan 2021 31 Dec 2021 10-K 01 Mar 2022 2021 FY
2020 $16,135,000 +$11,478,000 +246% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
2019 $4,657,000 +$3,276,000 +237% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $1,381,000 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.